The forecasted sales values of antiinfective medicine in Norway from 2024 to 2028 are consistently 8.5 as a percentage of Total Sales. This shows a stable trend without any fluctuation year-on-year or any variation over the last two years. Since our analysis starts in 2024, the Year 2023 data is not provided, hence no CAGR can be computed.
Future trends to watch for may include potential impact of emerging drug resistances, changes in healthcare policies, and advancements in antiinfective innovations. Monitoring these factors will be crucial for anticipating market dynamics and future adjustments in sales distributions.
